Compare Mesoblast Limited (MESO) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Atlassian Corporation PLC — how do they compare? Mesoblast Limited trades at $14.1 (market cap $1.75B), while Atlassian Corporation PLC trades at $206.02 (market cap $51.53B). The key difference: Atlassian Corporation PLC is far larger — about 29.4× Mesoblast Limited's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Atlassian Corporation PLC for 64 Days on average.
| MESO | TEAM | |
|---|---|---|
Market Cap | $1.75B | $51.53B |
Volume | 239,027 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $20.96 | $203.57 |
52-Week Low | $13.19 | $57.15 |
Typical Hold Time | 14 Days | 64 Days |
Enterprise Value | $1.83B | $51.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Atlassian (TEAM) trades at $195.67, up 0.87% with bullish technical signals and strong analyst support. The stock shows improving fundamentals with revenue growth from $2.8B in 2022 to $5.22B in 2025, though net margins remain negative. Recent earnings beats and AI-driven cloud adoption provide momentum, with the current price near resistance at $196.
Outlook remains positive given robust cloud growth and AI integration, but high valuations and persistent losses pose risks. Wall Street consensus is strongly bullish with 30 buy ratings and a $191.16 target, though the stock trades above this level. Key risks include execution challenges and competitive pressures in the enterprise software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
